Management of non-high-density lipoprotein abnormalities.

  title={Management of non-high-density lipoprotein abnormalities.},
  author={Robert S Rosenson},
  volume={207 2},
Epidemiological evidence supports the use of non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B-100 (apoB), and low-density lipoprotein particles as markers of atherogenic risk. Treatment guidelines also identify these as additional targets of lipid-modifying intervention in patients with elevated triglycerides (TG). Even when TG are only moderately elevated, many patients on statin monotherapy who have achieved targets for low-density lipoprotein cholesterol (LDL-C) fail to… CONTINUE READING
14 Extracted Citations
62 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 14 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 62 references

Efficacy and safety of ABT - 335 ( fenofibric acid ) in combination with rosuvastatin in patients with mixed dyslipidemia : a phase 3 study

  • PH Jones, MH Davidson
  • Atherosclerosis
  • 2009

Similar Papers

Loading similar papers…